<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>46</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Didier Breyer</style></author><author><style face="normal" font="default" size="100%">Philippe Herman</style></author><author><style face="normal" font="default" size="100%">Brandenburger,A.</style></author><author><style face="normal" font="default" size="100%">Gheysen,G.</style></author><author><style face="normal" font="default" size="100%">Remaut,E.</style></author><author><style face="normal" font="default" size="100%">Soumillion,P.</style></author><author><style face="normal" font="default" size="100%">J. Van Doorsselaere</style></author><author><style face="normal" font="default" size="100%">Custers,R.</style></author><author><style face="normal" font="default" size="100%">Katia Pauwels</style></author><author><style face="normal" font="default" size="100%">Myriam Sneyers</style></author><author><style face="normal" font="default" size="100%">Reheul,D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Should novel organisms developed using oligonucleotide-mediated mutagenesis be excluded from the EU Regulation</style></title><secondary-title><style face="normal" font="default" size="100%">ISB news report</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">EU</style></keyword><keyword><style  face="normal" font="default" size="100%">mutagenesis</style></keyword><keyword><style  face="normal" font="default" size="100%">New techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Paper</style></keyword><keyword><style  face="normal" font="default" size="100%">regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Regulatory</style></keyword><keyword><style  face="normal" font="default" size="100%">SAFETY</style></keyword><keyword><style  face="normal" font="default" size="100%">SBB</style></keyword><keyword><style  face="normal" font="default" size="100%">Technique</style></keyword><keyword><style  face="normal" font="default" size="100%">use</style></keyword><keyword><style  face="normal" font="default" size="100%">website</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">0/0/2009</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">12</style></number><publisher><style face="normal" font="default" size="100%">ISBN</style></publisher><pub-location><style face="normal" font="default" size="100%">Brussels</style></pub-location><volume><style face="normal" font="default" size="100%">November 2009</style></volume><pages><style face="normal" font="default" size="100%">2 - 12</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;This paper discusses regulatory and safety issues associated with the use of oligonucleotide-mediated mutagenesis and provides scientific arguments for not having organisms developed through this technique fall within the scope of the EU regulation of GMOs.&lt;/p&gt;
</style></abstract><custom1><style face="normal" font="default" size="100%">38519</style></custom1><section><style face="normal" font="default" size="100%">2</style></section></record></records></xml>